IntriCon to launch new CDM device at 2009 AHA Scientific Sessions

NewsGuard 100/100 Score

IntriCon Corporation (NASDAQ: IIN), a designer, developer, manufacturer and distributor of body-worn medical and electronics devices, announced today that it will unveil a prototype of its new Cardiac Diagnostic Monitoring (CDM) device, called the Mobile Patient ECG Telemetry System, or MPETS, at the 2009 American Heart Association (AHA) Scientific Sessions, Nov. 15-17, in Orlando, Fla.

At booth 1663 in the Orange County Convention Center, IntriCon/Datrix will introduce the MPETS, a next-generation wireless outpatient monitoring tool, which uses a proven automatic arrhythmia detection algorithm.

“This is an exciting time for IntriCon—and great news for cardiac diagnostic OEMs and their patients,” said Mark S. Gorder, president and chief executive officer at IntriCon. “We have leveraged Datrix’s cardiac monitoring capabilities and IntriCon’s marketing abilities to develop a new wireless cardiac monitoring device that allows for more patient comfort and the ability to identify asymptomatic cardiac events including atrial fibrillation, Brady arrhythmia, tachy arrhythmia and cardiac pause.”

In August 2009, IntriCon acquired Datrix, an Escondido, Calif.-based supplier of CDM devices, to leading medical OEMs. IntriCon’s capabilities combined with Datrix’s, creates a platform for IntriCon to expand into other physiological monitoring markets. And adding the wireless outpatient telemetry capability gives the company access to the emerging biotelemetry space.

The AHA’s Scientific Sessions is the premier cardiovascular meeting that includes programming in three broad areas of clinical, basic and population science as well as cross-disciplinary translational science.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New technology uses a smartphone to analyze heart movement, detect heart failure